



16 August 2010

The Company Announcements Platform  
ASX Ltd  
Sydney NSW 2000

### **Agreement Update**

Phylogica Limited advises that the signing of formal documentation with a large pharmaceutical and biotechnology group regarding a new research partnership utilizing the Company's proprietary library of protein fragments (Phylomer peptides) is now imminent.

Details of the agreement will be released as soon as the formal documentation has been completed and the company will then request lifting of its current trading suspension.

### **For further information, please contact:**

Dr Paul Watt  
CEO  
Tel: +61 8 9382 8888  
Mobile: +61 417 986 005  
[paulw@phylogica.com](mailto:paulw@phylogica.com)

\*\*\*\*\*

### **About Phylogica ([www.phylogica.com](http://www.phylogica.com))**

Phylogica is a leading drug discovery company (ASX; PYC) that has developed proprietary peptide (Phylomer<sup>®</sup>) libraries derived from sequenced biodiverse bacterial genome from some of the world's most extreme environments, such as terrestrial and deep-sea volcanic vents and geysers. This biodiversity has yielded peptides with unique drug-like structures and Phylogica has extensive data to validate the high quality of hits against different target classes, in addition to n vivo proof of concept of drug candidates and potential administration by a number of means, including parenteral or intranasal delivery. Phylogica aims to achieve rapid cash sustainability from the provision of fee-for-service screening of its peptide libraries against third-party targets, but to retain down-stream value through milestone payments and royalties for any resulting product candidate.

PO Box 8207, Subiaco East, Western Australia 6008  
Level 22 Allendale Square, 77 St Georges Tce, Perth, Western Australia 6000  
Tel: +61 8 93828888 Fax: +61 8 93258088  
[www.phylogica.com](http://www.phylogica.com)  
ABN 48 098 391 961

For personal use only